Alarming Rise in Incidence of Zika-related Birth Defects

San Francisco, California, May, 09, 2017: TMR Research presents a new report on the global Zika virus vaccine market for the 2017-2025 period. The report, titled “Zika Virus Vaccines Market – Global Industry Analysis, Size, Share, Trends, Analysis, Growth, and Forecast 2017 – 2025,” report serves as a useful tool for understanding the developmental aspects of global Zika virus vaccine market and its ancillary industries. It provides a detailed description of the vital market indicators and changing competitive hierarchy that are expected to have a bearing on this market for the aforementioned forecast period. Furthermore, the various market segments are studied and growth projections are presented at both regional and global level.

The growing prevalence of Zika virus infection is the primary factor driving the global Zika virus vaccine market. This, along with the increasing incidence of Zika fever is leading to the development of potent vaccines. The rising awareness about treatment option for Zika virus is furthering the market’s growth.

Zika virus infection is transferable. It can pass from an infected mother to her fetus. This results in the infant to be born with microcephaly and other birth defects. This has necessitated the development of vaccines for the prevention of Zika-related birth defects. For example, as per data from Brazilian state authorities, since 2014, more than 1,638 babies in the country were born with microcephaly. The alarming rise in Zika-related birth defects is creating a dire need for development of vaccines to address it.

In November 2016, Zika infection was freed from being an epidemic, as announced by the World Health Organization. The infection is expected to be less prevalent in the coming years, thereby limiting developmental initiatives for Zika virus infection. This, in turn, is restraining the market from realizing its full potential.

The Zika virus vaccine market can be studied with respect to the regional segments of North America, Asia Pacific, Europe, and Rest of the World. Among these, the Rest of the World regional segment is expected to be a significant market during the forecast period. The increasing patient pool suffering from Zika virus infection is the key factor driving the demand for these vaccines in this region. Brazil presently records the highest number of individuals suffering from the infection and is closely followed by Columbia and Venezuela.

The report studies the competitive landscape of the global Zika virus vaccine market at length. Being capital intensive world’s leading drug manufacturers are involved in this industry. This includes Takeda Pharmaceutical Co. Ltd., NewLink Genetics Co., GeneOne Life Science Inc., Sanofi S.A., Hawaii Biotech Inc., Immunovaccine Inc., Bharat Biotech International Ltd., Inovio Pharmaeuticals Inc., and GlaxoSmithKline Plc.